Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Mar 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: AQST
TL;DR
AQST filed an 8-K on 3/10/25 - standard corporate update.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on March 10, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 30 Technology Drive, Warren, NJ 07059, with a principal business phone number of 908-941-1900. The company was formerly known as MonoSol Rx, Inc., with a name change effective May 7, 2007.
Why It Matters
This 8-K filing provides an update on Aquestive Therapeutics' corporate information and regulatory disclosures, which is important for investors to stay informed about the company's official reporting status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain any material non-public information that would significantly impact the company's risk profile.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- 30 Technology Drive, Warren, NJ 07059 (location) — Principal Executive Offices
- 908-941-1900 (phone_number) — Principal Business Phone
- MonoSol Rx, Inc. (company) — Former Company Name
- May 7, 2007 (date) — Date of Name Change
FAQ
What is the primary purpose of this 8-K filing for Aquestive Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits, as indicated in the filing details.
What is the principal business address of Aquestive Therapeutics, Inc.?
The principal business address of Aquestive Therapeutics, Inc. is 30 Technology Drive, Warren, NJ 07059.
What was Aquestive Therapeutics, Inc. formerly known as?
Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx, Inc.
When was the name change from MonoSol Rx, Inc. to Aquestive Therapeutics, Inc. effective?
The name change was effective on May 7, 2007.
What is the telephone number for Aquestive Therapeutics, Inc.'s principal executive offices?
The telephone number for Aquestive Therapeutics, Inc.'s principal executive offices is (908) 941-1900.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 regarding Aquestive Therapeutics, Inc. (AQST).